{"id":"W2060632341","doi":"10.1016/j.bbmt.2013.08.002","title":"Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Takeda Oncology; Health Resources and Services Administration; IC Design Education Center; Astellas Pharma; Eisai; Genentech; CellGenix; Therakos; Sigma-Tau Pharmaceuticals; Medical College of Wisconsin; StemCyte; BioMarin Pharmaceutical; U.S. Navy; Celgene; Osiris Therapeutics; WellPoint; HistoGenetics; Teva Pharmaceutical Industries; Otsuka America; Pfizer; Biogen; AABB; U.S. Department of Defense; Sanofi; Amgen; Blue Cross and Blue Shield Association; U.S. Department of Health and Human Services; Astellas Pharma US; National Cancer Institute; Gilead Sciences","keywords":"Medicine; Multiple myeloma; Lenalidomide; Cohort; Thalidomide; Bortezomib; Internal medicine; Transplantation; Multivariate analysis; Autologous stem-cell transplantation; Hematopoietic stem cell transplantation; Oncology; Surgery","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008523299,0.00009426564,0.0001875006,0.001167036,0.0001829153,0.0005697575,0.0003603206,0.0003723619,0.0004945681],"category_scores_gemma":[0.003018549,0.0000997383,0.0002916422,0.001887783,0.0002420045,0.0004702684,0.0003090132,0.0005344898,0.0001140998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039039,"about_ca_system_score_gemma":0.0008552134,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03296967,"about_ca_topic_score_gemma":0.04238396,"domain_scores_codex":[0.9992924,0.0001018075,0.0001181062,0.0001390166,0.0002157977,0.0001328618],"domain_scores_gemma":[0.9943601,0.0005661191,0.003523111,0.0001237494,0.0008561482,0.0005707129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005034521,0.00002073145,0.9950573,0.00001475894,0.00002327986,0.00003688589,0.00004493234,0.0000944777,0.00007896979,0.00003700632,0.0003593914,0.00418185],"study_design_scores_gemma":[0.000003464152,0.00004845069,0.9990404,0.00001415106,0.00001058097,0.000181437,0.00008785594,0.0001811754,0.00006391748,0.00001193742,0.0003541336,0.000002273817],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950819,0.002476377,0.00009172063,0.0004003103,0.00001300785,0.000005526832,0.001231107,0.000008943257,0.0006909519],"genre_scores_gemma":[0.996672,0.001539023,0.0001039364,0.0001184327,0.00003278604,0.000007430467,0.001361873,0.00000306422,0.0001613881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03296967,"threshold_uncertainty_score":0.06555551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03081379634762552,"score_gpt":0.3165390970510847,"score_spread":0.2857253007034592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}